Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04155840 · ClinicalTrials.gov registry record · Phase 2
Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT04155840: Clinical Trial Phase 2 study, sponsored by University of Washington.
NCT04155840 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04155840, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This trial studies how well bendamustine and rituximab in combination with copanlisib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as bendamustine and rituximab, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Copanlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bendamustine and rituximab with copanlisib may work better than bendamustine and rituximab alone in treating chronic lymphocytic leukemia or small lymphocytic lymphoma.
Primary Outcome
Will use a Simon optimal two-stage design.
Interventions
- BIOLOGICAL Rituximab
- DRUG Bendamustine
- DRUG Copanlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2021-03-16 |
| Phase | Phase 2 |
Why NCT04155840 stopped before completion
NCT04155840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 3 interventions - of which Rituximab is the first listed.
NCT04155840 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04155840 about?
NCT04155840 is a clinical study titled "Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". This trial studies how well bendamustine and rituximab in combination with copanlisib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as bendamustine and rituximab, work in different ways to stop the growth of cancer cells, ...
What is the current status of trial NCT04155840?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2020-01-31. Estimated completion is 2021-03-16.
What interventions are being tested in trial NCT04155840?
The interventions under investigation include: Rituximab (BIOLOGICAL), Bendamustine (DRUG), Copanlisib (DRUG).
Who is sponsoring clinical trial NCT04155840?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04155840's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI